Get the Stockscreener App
31.58
0.13%
-0.04
After Hours:
31.58
Rigel Pharmaceuticals stock is traded at $31.58, with a volume of 473.37K.
It is down -0.13% in the last 24 hours and up +11.47% over the past month.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.
See More
Previous Close:
$31.62
Open:
$32
24h Volume:
473.37K
Relative Volume:
0.69
Market Cap:
$566.46M
Revenue:
$116.88M
Net Income/Loss:
$-25.09M
P/E Ratio:
-225.57
EPS:
-0.14
Net Cash Flow:
$-20.74M
1W Performance:
+5.37%
1M Performance:
+11.47%
6M Performance:
+61.45%
1Y Performance:
+131.69%
1-Day Range:
$31.21
$32.90
1-Week Range:
$29.14
$32.90
52-Week Range:
$13.64
$43.72
Rigel Pharmaceuticals Stock (RIGL) Company Profile
Name
Rigel Pharmaceuticals
Sector
Industry
Phone
650-624-1100
Address
611 GATEWAY BOULEVARD, SUITE 900, SOUTH SAN FRANCISCO, CA
Compare RIGL with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RIGL
Rigel Pharmaceuticals
|
31.58 | 567.18M | 116.88M | -25.09M | -20.74M | -0.14 |
|
VRTX
Vertex Pharmaceuticals Inc
|
425.57 | 107.66B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
651.80 | 68.74B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
456.04 | 58.93B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
818.50 | 50.51B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
189.60 | 41.29B | 447.02M | -1.18B | -868.57M | -6.1812 |
Rigel Pharmaceuticals Stock (RIGL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-03-23 | Resumed | Piper Sandler | Neutral |
| Jun-09-22 | Downgrade | Citigroup | Buy → Neutral |
| Jun-08-22 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Jun-08-22 | Downgrade | Piper Sandler | Overweight → Neutral |
| Mar-23-22 | Initiated | B. Riley Securities | Neutral |
| Nov-09-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Nov-15-19 | Resumed | Cantor Fitzgerald | Overweight |
| Sep-26-19 | Resumed | JP Morgan | Overweight |
| Mar-01-19 | Reiterated | Cantor Fitzgerald | Overweight |
| Aug-27-18 | Initiated | Citigroup | Buy |
| May-02-18 | Reiterated | Cantor Fitzgerald | Overweight |
| Dec-21-17 | Resumed | Piper Jaffray | Overweight |
| Dec-15-17 | Initiated | Cantor Fitzgerald | Overweight |
| Nov-06-17 | Resumed | H.C. Wainwright | Buy |
| Mar-09-17 | Reiterated | H.C. Wainwright | Buy |
| Aug-31-16 | Reiterated | H.C. Wainwright | Buy |
| Aug-30-16 | Reiterated | Piper Jaffray | Overweight |
| Jul-13-16 | Initiated | H.C. Wainwright | Buy |
| Jun-13-16 | Initiated | Piper Jaffray | Overweight |
| Apr-22-16 | Upgrade | JP Morgan | Neutral → Overweight |
| Apr-08-13 | Reiterated | Stifel | Buy |
| Nov-29-12 | Initiated | UBS | Neutral |
| Nov-06-12 | Reiterated | Oppenheimer | Outperform |
| Mar-26-12 | Initiated | Canaccord Genuity | Hold |
| Dec-10-10 | Downgrade | MP Advisors | Outperform → Market Perform |
View All
Rigel Pharmaceuticals Stock (RIGL) Latest News
Can Rigel Pharmaceuticals Inc. stock deliver strong Q4 earningsWeekly Investment Recap & Daily Stock Momentum Reports - newser.com
Can a trend reversal in Rigel Pharmaceuticals Inc. lead to recoveryDollar Strength & Daily Profit Focused Screening - newser.com
Will Rigel Pharmaceuticals Inc. stock reach Wall Street targetsTrade Volume Summary & Weekly Stock Breakout Alerts - newser.com
Detecting price anomalies in Rigel Pharmaceuticals Inc. with AIQuarterly Trade Summary & Trade Opportunity Analysis Reports - newser.com
Is Rigel Pharmaceuticals Inc. stock a contrarian buyNew Guidance & Safe Entry Trade Reports - newser.com
What momentum shifts mean for Rigel Pharmaceuticals Inc.July 2025 Final Week & Risk Adjusted Buy and Sell Alerts - newser.com
Is Rigel Pharmaceuticals Inc. stock recession proofEarnings Beat & Verified High Yield Trade Plans - newser.com
Published on: 2025-11-02 12:30:33 - newser.com
Can machine learning forecast Rigel Pharmaceuticals Inc. recoveryMarket Performance Summary & Risk Controlled Swing Alerts - newser.com
Can you recover from losses in Rigel Pharmaceuticals Inc.Rate Cut & Low Drawdown Momentum Trade Ideas - newser.com
Can Rigel Pharmaceuticals Inc. stock hit analyst price targets2025 Biggest Moves & Free High Accuracy Swing Entry Alerts - newser.com
Why Rigel Pharmaceuticals Inc. stock could see breakout soonWeekly Loss Report & AI Driven Price Predictions - newser.com
Can Rigel Pharmaceuticals Inc. (RI2) stock ride next bull market cycleFed Meeting & High Accuracy Swing Entry Alerts - newser.com
What is the fair value estimate for Rigel Pharmaceuticals Inc. (RI2) stock in 2025Earnings Overview Report & AI Powered Trade Plan Recommendations - newser.com
Will earnings trigger a reversal in Rigel Pharmaceuticals Inc.Quarterly Risk Review & Weekly Return Optimization Alerts - newser.com
Measuring Rigel Pharmaceuticals Inc.’s beta against major indices2025 Macro Impact & Free Safe Capital Growth Stock Tips - newser.com
Why pension funds invest in Rigel Pharmaceuticals Inc. (RI2) stockJobs Report & Growth Focused Investment Plans - newser.com
Why Rigel Pharmaceuticals Inc. stock remains undervalued2025 Stock Rankings & Real-Time Volume Triggers - newser.com
Will Rigel Pharmaceuticals Inc. (RI2) stock enhance shareholder valueLong Setup & Safe Capital Growth Stock Tips - newser.com
Will Rigel Pharmaceuticals Inc. (RI2) stock outperform value peersPortfolio Risk Report & AI Driven Price Predictions - newser.com
Rigel Pharmaceuticals Inc expected to post earnings of 85 cents a shareEarnings Preview - TradingView
Rigel Gears Up to Report Q3 Earnings: Here's What to Expect - sharewise.com
Rigel Pharmaceuticals CEO outlines biotech growth strategy in CNBC interview - Traders Union
Rigel Pharmaceuticals (RIGL) Projected to Post Quarterly Earnings on Thursday - MarketBeat
News impact scoring models applied to Rigel Pharmaceuticals Inc.Earnings Beat & Accurate Technical Buy Alerts - newser.com
Candlestick signals on Rigel Pharmaceuticals Inc. stock todayJuly 2025 Intraday Action & Daily Stock Trend Reports - newser.com
Composite Rating For Rigel Pharmaceuticals Rises To 96 - Investor's Business Daily
Rigel Pharmaceuticals Inc. stock volume spike explainedInsider Buying & Weekly Market Pulse Alerts - newser.com
What machine learning models say about Rigel Pharmaceuticals Inc.Long Setup & Reliable Breakout Stock Forecasts - newser.com
Rigel Pharmaceuticals Stock (RIGL) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.62%
0.21%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):